All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Autifony Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme

Lead Product(s): AUT00206

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AUT00206

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: $50.1 million Upfront Cash: $29.5 million

Deal Type: Termination August 26, 2020

Details:

Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.